PRESS RELEASE
For Immediate Release
Date: 14 October 2025
Contact: Evelyn Liew
evelyn@ucrest.net
UCrest Berhad
6 Floor, Unit 4, 8 First Avenue,
Bandar Utama, 47800 Petaling Jaya,
Selangor Malaysia
Phone: +603-7728 9880
Fax : +603-7728 1080
UCrest Berhad (Stock Code: UCREST 0005)
UCrest Berhad Awarded Its First Patent in Taiwan for AI-Powered Digital Health Platform, iMedic™
PETALING JAYA, 14 October 2025 – UCrest Berhad (“UCrest” or “the Company”) is pleased to announce that the Company has been granted its first patent in Taiwan for its flagship product iMedic™, an Artificial Intelligence (AI)-powered digital health platform.
The patent granted covers AI-driven health management and its methods for telemedicine services, marking a major achievement in UCrest’s intellectual property journey and reinforcing its leadership in the global digital healthcare industry. The patent protects the Company’s innovations in AI-powered diagnostics, personalized health analytics, and remote patient management, strengthening iMedic™’s position as a leading platform connecting patients, doctors, and healthcare institutions seamlessly across borders.
Pioneered in digital health, the core technologies of iMedic™ are powered by Artificial Intelligence (AI), Internet of Things (IoT), Blockchain, and data analytics integrated with a robust Electronic Medical Records (EMR) system. This combination of intelligent connectivity and secure data infrastructure enables iMedic™ to deliver highly personalized healthcare, continuous monitoring, and predictive analytics for preventive care and chronic disease management.
Over the past three years, UCrest has filed a total of seven patents covering various aspects of its AI health technologies and platform architecture. These filings include:
- 2 patents in the United States;
- 2 patents in Taiwan;
- 1 patent in China;
- 1 patent in Europe; and
- 1 global filing under the Patent Cooperation Treaty (PCT).
The PCT (Patent Cooperation Treaty) filing provides UCrest with a strategic gateway to seek patent protection in more than 150 countries through a single international application. This enables the Company to efficiently manage and expand its intellectual property portfolio across major global markets. By leveraging the PCT framework, UCrest gains:
- Extended time and flexibility (up to 30 months) to determine which countries to pursue national patents;
- Significant cost efficiency in translation, legal, and filing processes;
- Early international examination and feedback on the novelty and patentability of its technologies; and
- A stronger global position for technology licensing, commercialization, and strategic partnerships.
Through its PCT filing, UCrest reinforces its commitment to protecting and commercializing its innovations globally, ensuring that its proprietary technologies in AI, IoT, and Blockchain-driven digital health remain well-defended and monetizable across multiple jurisdictions.
“We are proud to have received our first patent approval in Taiwan, which validates the originality and depth of our innovation in digital health,” said Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad. “Our strategy to file globally through the PCT demonstrates our vision to establish iMedic™ as a leading international digital health platform. These patents strengthen our IP assets and open new opportunities for global collaborations and licensing.”
UCrest’s iMedic™ platform leverages advanced AI algorithms to analyze medical data, assist doctors in diagnosis, and enable continuous remote care. It has been deployed in multiple markets across Asia and beyond, supporting hospitals, clinics, and healthcare providers in delivering more efficient, personalized, and accessible healthcare services.
The Company will continue to innovate and lead the digital health industry through advanced research and development. UCrest expects to file many more patents in the near future as it further expands the technological capabilities and applications of its iMedic™ platform.
This patent approval not only enhances UCrest’s competitive edge in digital health innovation but also reinforces its value proposition to global partners, investors, and healthcare institutions as it continues to expand its international footprint.
ABOUT UCREST BERHAD
UCrest Berhad (ACE Market: UCREST 0005) is a leading digital health technology company that develops and operates the iMedic™ cloud hospital platform, enabling patients to consult doctors, manage health records, and monitor chronic diseases remotely using advanced AI, IoT, Blockchain, and data analytics technologies. With operations and partnerships across Asia, the United States, and Europe, UCrest is committed to empowering patients and healthcare professionals through innovation and technology.
For investor relations, please contact:
Investor Relations Team
UCrest Berhad
Email: evelyn@ucrest.net
Website: www.ucrest.net
